2025年世界预览：波涛汹涌的大海

Today’s Presenters2DANIEL CHANCELLORVP Thought Leadership ANNA OSBORNEAssociate Director MELANIE SENIORAuthorWorld Preview 2025 WORLD PREVIEW REPORT – NOW AVAILABLE WORLD PREVIEW REPORT: KEY HIGHLIGHTS•Drug sales forecasts to 2030 reflect solid underlying demand with worldwide annualprescription sales of $1.75tn in 2030.•GLP-1s are in a class of their own. By 2030 they will account for close to 9% of allprescription drug sales - a CAGR of 20% to 2030•Immuno-inflammatory drugs also feature in the top 10 for 2030 and multi-indicationblockbusters are a focus for Big Pharma•Uncertainty remains with tariffs, an FDA in flux and potential changes to drug pricingpolicies•Dealmaking is quiet but there are $300bn in sales at risk through looming loss ofexclusivity – pipelines need to be filledAvailable onEvaluate.com OncologyGLP-1sCentral Nervous SystemImmunomodulatorsGastro-intestinal & Endocrine (ex GLP-1)CardiovascularVaccinesBloodRespiratoryMusculoskeletal-5%0%5%10%15%20%25%30%35%40%-5%0%5%10%15%20%25%2016–24 CAGR (%)2024–30 CAGR (%)Leading Therapy Areas in 2030 By Historical and Forecast Sales GrowthEvaluate 2025 | Copyright © 2025 Evaluate Ltd. All rights reserved. Source: Evaluate Pharma © (May 2025)AveragehistoricalCAGRAverage forecast CAGR 40292847189254631525.0%3.6%3.3%5.3%2.0%0.8%2.3%4.4%2.7%4.3%0204060801001202016201720182019202020212022202320242025Worldwide sales ($bn)Total Sales at Risk% Market at riskWorldwide Sales At Risk* From Patent ExpiryEvaluate 2025 | Copyright © 2025 Evaluate Ltd. All rights reserved. Source: Evaluate Pharma © (May 2025) $186bn$182bn$91bn221274231050100150200250300202020212022Deal value ($bn)Deal Value ($b)Mergers & Acquisitions 2020–25Evaluate 2025 | Copyright © 2025 Evaluate Ltd. All rights reserved. Source: Evaluate Pharma © (May 2025)